Inventiva to Unveil Breakthrough MASH Fibrosis Data at AASLD 2026

Inventiva, a French clinical-stage biopharmaceutical company, announced on [date] that it will present scientific abstracts at AASLD The Liver Meeting 2026, detailing preclinical data on its lead drug candidate lanifibranor. The data demonstrate that balanced activation of PPARα, PPARδ, and PPARγ by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesis.

The abstracts, to be presented at the annual meeting of the American Association for the Study of Liver Diseases, highlight lanifibranor's multi-target mechanism, which could offer a differentiated approach in the competitive MASH treatment landscape. Inventiva has been advancing lanifibranor through clinical trials, including the Phase 3 NATiV3 study, and this preclinical evidence may further support its potential to address fibrosis, a key driver of disease progression.

The presentations at AASLD 2026 could draw significant attention from investors and industry peers, as the MASH space has seen increased activity with recent approvals and late-stage readouts. Positive reception may reinforce Inventiva's position and could impact partnership or licensing discussions. The company is expected to release full data during the conference, with potential implications for future clinical development and regulatory strategies.